89
total announcements
543245.BO · 15 min delayed
Gland Pharma Ltd
Gland Pharma Ltd has announced a schedule of analyst/institutional investor meetings, including a one-on-one meeting with Kotak Mutual Fund on September 09, 2026.
Gland Pharma Ltd
Gland Pharma Ltd has concluded the USFDA inspection at its facilities in Visakhapatnam, with zero observations. The inspection was conducted between August 22, 2022, and September 11, 2022, and was passed with zero Form 483 observations.
Gland Pharma Ltd
Gland Pharma Ltd has announced a schedule of investor meets under Regulation 30 of LODR, intimating the same to the exchanges. The meets are scheduled from September 3 to November 22, 2022, and will be attended by the company's management. The meets are subject to change and may be affected by exigencies on the part of the investor/company.
Gland Pharma Ltd
Gland Pharma Ltd has announced the voting results of its 48th AGM, along with the scrutinizer's report. The company has received 11,199,667,722 votes, with 55 resolutions passed. The resolutions include the adoption of the audited financial statements for the year ended March 31, 2022, including the audited balance sheet as at March 31, 2022, and the statement of profit and loss for the year ended March 31, 2022.
Gland Pharma Ltd
Gland Pharma Ltd held its 48th Annual General Meeting (AGM) on August 25, 2022, where the company's shareholders approved the appointment of Mr. Srinivas Sadasiva as the Executive Chairman. The company also presented its annual report and accounts for the year ended March 31, 2022, and discussed its journey of quality, growth, and value creation.
Gland Pharma Ltd
Gland Pharma Ltd has announced a schedule of investor meets with analysts and institutional investors on August 26, 27, and 28, 2023.
Gland Pharma Ltd
Gland Pharma Ltd has announced its Q1FY27 earnings call transcript. The company's management discussed its performance, growth prospects, and future plans.
Gland Pharma Ltd
Gland Pharma Ltd announced the appointment of Mr. Deepak Sappar as the Chief Executive Officer of the company, effective from November 16, 2022. Mr. Sappar has over 27 years of executive experience, including 23 years in the pharmaceutical industry. He will lead the company's global business expansion, services, API, and product launches across key markets including the US, Europe, Japan, Brazil, China, Mexico, the Middle East, Africa, and Asia.
Gland Pharma Ltd
Gland Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the results available on its website and stock exchanges.
Gland Pharma Ltd
Gland Pharma Ltd announced its Q1FY27 earnings call audio recording, with the call held on August 11, 2023, at 11:00 AM. The company's earnings call was recorded and uploaded on its website. The call was attended by the company's management and was in compliance with the regulations of the Indian stock exchange.
Gland Pharma Ltd
Gland Pharma Ltd has announced a schedule of investor meets, including one-on-one meetings with the company's management, to be held on August 11, 13, 20, and 22, 2023. The meetings are subject to change and may be affected by exigencies on the part of the investor/analyst community.
Gland Pharma Ltd
Gland Pharma Ltd has released its Q1FY27 financial results, with revenue from operations at ₹118.88 crore, other income at ₹66.12 crore, and total income at ₹118.88 crore. Gross profit was ₹11.11 crore, with a margin of 9.33%. The company has also provided a detailed presentation on its business and future plans.
Gland Pharma Ltd
Gland Pharma Ltd has announced its Q1FY27 financial results, with the company's revenue and profit after tax (PAT) increasing by 22.5% and 24.5% respectively, compared to the same period last year. The company's EBITDA margin has also improved to 24.5% from 22.5% in the same period last year.
Gland Pharma Ltd
Gland Pharma Ltd's board meeting outcome for unaudited financial results for the quarter ended June 30, 2026, has been approved with the company's results being prepared in compliance with Indian Accounting Standards. The board meeting was held on August 11, 2026, and the unaudited financial results for the quarter ended June 30, 2026, have been prepared in accordance with the Listing Obligations and Disclosure Requirements of the Securities and Exchange Board of India.
Gland Pharma Ltd
Gland Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the board meeting held on August 10, 2022. The company has reported a profit of Rs. 44.00 Cr. and a revenue of Rs. 225.50 Cr. for the quarter.
Gland Pharma Ltd
Gland Pharma Ltd announced a strategic partnership with a global pharmaceutical company for manufacturing and supply of sterile injectable products. The partnership is expected to provide strong long-term business support and improve the company's product life cycle, with a focus on development, process, quality, and regulatory support.
Gland Pharma Ltd
Gland Pharma Ltd has announced a strategic collaboration with Neuland Laboratories for sterile API manufacturing. The partnership will enable Gland Pharma to expand its sterile manufacturing capacity and serve growing demand for sterile injectables in the global market.
Gland Pharma Ltd
Gland Pharma Ltd has announced the notice of its 48th Annual General Meeting (AGM) to be held on August 25, 2026, through video conferencing. The company has also disclosed dividend information and e-voting details.
Gland Pharma Ltd
Gland Pharma Ltd dispatched its 48th AGM Notice and Annual report for FY 2025-26. The report includes details on the company's performance, financials, and governance. The AGM notice mentions the meeting date, time, and venue. The report also includes the company's financial statements, auditor's report, and other relevant information.
Gland Pharma Ltd
Gland Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the year ended March 31, 2026, which includes details of its corporate governance, sustainability, and social responsibility initiatives.